GOSSAnother day, another complaint
Gossamer Bio is back in the legal hot seat. Philadelphia firm Berger Montague PC says it has filed a class action lawsuit on behalf of investors who bought Gossamer shares between June 16, 2025 and February 20, 2026.
Why investors should care
This isn’t just paperwork cosplay. Class-action headlines can keep pressure on a biotech name because they add a fresh layer of uncertainty, legal costs, and headline risk — basically the stock-market version of stepping on a rake twice.
The notice also sets a June 1, 2026 deadline for investors who want to seek lead-plaintiff status. That’s the legal equivalent of, “If you want the captain’s chair, speak now.”
Big picture
Gossamer Bio has been collecting lawsuit chatter like it’s trading cards, and the market usually doesn’t love that. Even when no cash changes hands yet, these cases can hang over sentiment and make it harder for the stock to catch a clean bid.